Cara Therapeutics (CARA) Reports Q1 Loss, Misses Revenue Estimates
CARACara Therapeutics(CARA) Zacks Investment Research·2024-05-14 06:11

Cara Therapeutics (CARA) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.49 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -47.37%. A quarter ago, it was expected that this biotechnology company would post a loss of $0.57 per share when it actually produced a loss of $0.59, delivering a surprise of -3.51%.Over the last four quarters, the com ...